Sep 2026· International Health Sciences Review· Vol 2· 0 citations
TL;DR
The evidence supports the International League Against Epilepsy definition based on failure of two tolerated, appropriately chosen and adequately used antiseizure medication schedules to achieve sustained seizure freedom, provided that pseudoresistance has been excluded.
Abstract
Drug-resistant epilepsy is a clinically consequential state in which continued medication trials yield progressively diminishing probabilities of sustained seizure freedom while exposure to injury, cognitive and psychiatric burden, social restriction, and epilepsy-related mortality persists. This narrative review examines the operational criteria for defining drug resistance and the clinical reasoning that should trigger surgical evaluation. A focused literature search was conducted in September 2026 using PubMed/MEDLINE, International League Against Epilepsy resources, and National Association of Epilepsy Centers guidance. Priority was given to consensus definitions, referral recommendations, randomized trials, systematic reviews, meta-analyses, and contemporary studies of presurgical evaluation and surgical outcomes. The evidence supports the International League Against Epilepsy definition based on failure of two tolerated, appropriately chosen and adequately used antiseizure medication schedules to achieve sustained seizure freedom, provided that pseudoresistance has been excluded. Once this threshold is reached, referral to a comprehensive epilepsy center should occur without waiting for multiple additional drug failures. Surgical candidacy depends on the ability to define an epileptogenic network that can be treated with acceptable functional risk. Resective or ablative procedures offer the greatest chance of seizure freedom in selected focal epilepsies, whereas disconnection and neurostimulation provide meaningful alternatives when curative surgery is not feasible.
Continued advances in imaging, electrophysiology, minimally invasive techniques, and neuromodulation are transforming the management of DRE and facilitating increasingly individualized treatment strategies.
Vartika Gupta, Pankaj Gupta· Asian Journal of Neurosurger...· 0 citations
Underutilization persists as a major and partly remediable problem, and the welcome diffusion of minimally invasive options should not eclipse resective and disconnective surgery, which remain the only potentially curative options validated by RCTs.
Current and emerging pharmacotherapeutic options for selected representative pediatric focal epilepsies are summarized using a syndrome- and localization-oriented approach, highlighting conventional antiseizure medications, newer agents, and investigational or repurposed treatments.
L. Perilli, G. Dell’Isola, Pietro Ferrara et al.· Expert Opinion on Pharmacoth...· 0 citations
This critical narrative review synthesises evidence on the clinical features, aetiologies, and therapeutic options for these syndromes, and evaluates the strength, consistency, and limitations of that evidence rather than cataloguing individual studies.
S. Bittmann, E. Luchter, E. Moschuring-Alieva· Asian Journal of Pediatric R...· 0 citations
OBJECTIVE
Deep brain stimulation (DBS) is an emerging treatment option for pediatric drug-resistant epilepsy (DRE), but evidence regarding its long-term efficacy and safety remains limited. We aimed to assess the long-term efficacy and safety of DBS in children with DRE at a minimum follow-up of 12 months.
METHODS
A...
Asmaa Mhanna, Michael A. Ciliberto, S. Ganganna et al.· Seizure· 0 citations
Seizures after acquired brain injury pose distinct therapeutic questions: early seizure prophylaxis, treatment of acute symptomatic seizures, and late epilepsy prevention. These endpoints are often conflated, although early seizure suppression does not establish disease-modifying antiepileptogenesis, these end points a...
Anil Chimakurthy, Viswabhaskar Susarla, J. H. Chaudhary et al.· BMC Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.